Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013

TY - JOUR

T1 - Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma

T2 - KEYNOTE-013

AU - Ribrag, Vincent

AU - Avigan, David E.

AU - Green, Damian J.

AU - Wise-Draper, Trisha

AU - Posada, Juan G.

AU - Vij, Ravi

AU - Zhu, Ying

AU - Farooqui, Mohammed Z.H.

AU - Marinello, Patricia

AU - Siegel, David S.

N1 - Funding Information: The authors thank the patients and their families and all investigators and site personnel. The authors also thank Jen-nifer Park, Karen Giallella, Brook Burton, Seth Thompson, Kathleen Fox (employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) and Roger Dansey (former employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) for their contributions to the development of the manuscript. Medical writing and/or editorial assistance was provided by Jacqueline Kolston, PhD, Doyel Mitra, PhD and Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

PY - 2019/8

Y1 - 2019/8

KW - PD-1 (PDCD1)

KW - multiple myeloma

KW - pembrolizumab

UR - https://www.scopus.com/pages/publications/85063689532

U2 - 10.1111/bjh.15888

DO - 10.1111/bjh.15888

M3 - Letter

C2 - 30937889

AN - SCOPUS:85063689532

SN - 0007-1048

VL - 186

SP - e41-e44

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -